Serum α-hydroxybutyrate dehydrogenase as a biomarker for predicting survival outcomes in patients with UTUC after radical nephroureterectomy

BMC Urol. 2024 Mar 20;24(1):62. doi: 10.1186/s12894-024-01439-2.

Abstract

Purpose: We aimed to determine the prognostic value of α-hydroxybutyrate dehydrogenase (α-HBDH) in upper tract urothelial carcinoma (UTUC) patients after radical nephroureterectomy (RNU).

Materials and methods: We retrospectively enrolled the data of 544 UTUC patients at West China Hospital from May 2003 to June 2019. Cancer-specific survival (CSS) was the endpoint of interest. The optimal cutoff value of α-HBDH was identified by X-Tile program. After propensity score matching (PSM), we utilized Kaplan‒Meier curves to estimate survival and Cox proportional hazard model for risk assessment. A nomogram was built based on the results of multivariate analysis, and calibration curve, time-dependent receiver operating characteristic (ROC) curves and decision curve analysis were also performed to evaluate the predictive accuracy.

Results: Overall, 394 and 150 patients were divided into the α-HBDH-low group and α-HBDH -high group at the cutoff value of 158 U/L, respectively. After PSM, the two groups were well matched for all confounding factors. High α-HBDH was associated with inferior CSS (P = 0.006), and preoperative α-HBDH was an independent predictor for CSS (HR: 1.36; 95% CI:1.08, 1.80), especially in localized UTUC patients (HR: 2.04; 95% CI:1.11, 3.74). Furthermore, the nomogram based on α-HBDH achieved great predictive ability for CSS with areas under the curves of 0.800 and 0.778 for 3-year and 5-year CSS, respectively.

Conclusion: Serum α-HBDH was a novel and reliable biomarker for predicting survival outcomes in UTUC patients after RNU but should be further explored.

Keywords: Biomarker; Outcome; Radical nephroureterectomy; Upper tract urothelial carcinoma; α-hydroxybutyrate dehydrogenase.

MeSH terms

  • Biomarkers
  • Carcinoma, Transitional Cell* / pathology
  • Humans
  • Hydroxybutyrate Dehydrogenase*
  • Nephroureterectomy / methods
  • Prognosis
  • Retrospective Studies
  • Urinary Bladder Neoplasms* / surgery
  • Urologic Neoplasms*

Substances

  • 2-hydroxybutyrate dehydrogenase
  • Biomarkers
  • Hydroxybutyrate Dehydrogenase